Insulin Degludec, a Novel Ultra-Long-Acting Basal Insulin versus Insulin Glargine for the Management of Type 2 Diabetes: A Systematic Review and Meta-Analysis
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1869-6961
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Insulin Degludec, a Novel Ultra-Long-Acting Basal Insulin versus Insulin Glargine for the Management of Type 2 Diabetes: A Systematic Review and Meta-Analysis ; day:24 ; month:4 ; year:2019 ; pages:1-18
Diabetes therapy ; (24.4.2019), 1-18
- Creator
-
Zhou, Wenchuan
Tao, Jinxin
Zhou, Xiaodong
Chen, Hongxia
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s13300-019-0624-4
- URN
-
urn:nbn:de:101:1-2019051722465693129360
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:58 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Zhou, Wenchuan
- Tao, Jinxin
- Zhou, Xiaodong
- Chen, Hongxia
- SpringerLink (Online service)
Other Objects (12)
A Review of Basal-Bolus Therapy Using Insulin Glargine and Insulin Lispro in the Management of Diabetes Mellitus
Switching the basal insulin to insulin glargine 300 u/ml in people with type 2 diabetes under basal insulin supported oral therapy – observational trial on effectiveness and safety
Impact of Switching from Twice-Daily Basal Insulin to Once-Daily Insulin Glargine 300 U/mL in People with Type 1 Diabetes on Basal–Bolus Insulin: Phase 4 OPTIMIZE Study
MYL1501D Insulin Glargine: A Review in Diabetes Mellitus
Combining GLP-1 Receptor Agonists and Basal Insulin in Older Adults with Type 2 Diabetes: Focus on Lixisenatide and Insulin Glargine
Treatment intensification using long-acting insulin –predictors of future basal insulin supported oral therapy in the DIVE registry
Fast-Acting Insulin Aspart: The Rationale for a New Mealtime Insulin
Efficacy and Safety of Switching Patients Inadequately Controlled on Basal Insulin to Insulin Glargine 300 U/mL: The TRANSITION 2 Study
Differences in metabolic and mitogenic signalling of insulin glargine and insulin aspart B10 in rats
Improved glycaemic control by switching from insulin NPH to insulin glargine: a retrospective observational study
Investigation of the Physico-Chemical Properties that Enable Co-Formulation of Basal Insulin Degludec with Fast-Acting Insulin Aspart
Insulin analogues dosing and costs - comparing real-life daily doses of insulin detemir and insulin glargine in type 2 diabetes patients
A Review of Basal-Bolus Therapy Using Insulin Glargine and Insulin Lispro in the Management of Diabetes Mellitus
Switching the basal insulin to insulin glargine 300 u/ml in people with type 2 diabetes under basal insulin supported oral therapy – observational trial on effectiveness and safety
Impact of Switching from Twice-Daily Basal Insulin to Once-Daily Insulin Glargine 300 U/mL in People with Type 1 Diabetes on Basal–Bolus Insulin: Phase 4 OPTIMIZE Study
MYL1501D Insulin Glargine: A Review in Diabetes Mellitus
Combining GLP-1 Receptor Agonists and Basal Insulin in Older Adults with Type 2 Diabetes: Focus on Lixisenatide and Insulin Glargine
Treatment intensification using long-acting insulin –predictors of future basal insulin supported oral therapy in the DIVE registry
Fast-Acting Insulin Aspart: The Rationale for a New Mealtime Insulin
Efficacy and Safety of Switching Patients Inadequately Controlled on Basal Insulin to Insulin Glargine 300 U/mL: The TRANSITION 2 Study
Differences in metabolic and mitogenic signalling of insulin glargine and insulin aspart B10 in rats
Improved glycaemic control by switching from insulin NPH to insulin glargine: a retrospective observational study
Investigation of the Physico-Chemical Properties that Enable Co-Formulation of Basal Insulin Degludec with Fast-Acting Insulin Aspart
Insulin analogues dosing and costs - comparing real-life daily doses of insulin detemir and insulin glargine in type 2 diabetes patients
A Review of Basal-Bolus Therapy Using Insulin Glargine and Insulin Lispro in the Management of Diabetes Mellitus
Switching the basal insulin to insulin glargine 300 u/ml in people with type 2 diabetes under basal insulin supported oral therapy – observational trial on effectiveness and safety
Impact of Switching from Twice-Daily Basal Insulin to Once-Daily Insulin Glargine 300 U/mL in People with Type 1 Diabetes on Basal–Bolus Insulin: Phase 4 OPTIMIZE Study
MYL1501D Insulin Glargine: A Review in Diabetes Mellitus
Combining GLP-1 Receptor Agonists and Basal Insulin in Older Adults with Type 2 Diabetes: Focus on Lixisenatide and Insulin Glargine
Treatment intensification using long-acting insulin –predictors of future basal insulin supported oral therapy in the DIVE registry
Fast-Acting Insulin Aspart: The Rationale for a New Mealtime Insulin
Efficacy and Safety of Switching Patients Inadequately Controlled on Basal Insulin to Insulin Glargine 300 U/mL: The TRANSITION 2 Study
Differences in metabolic and mitogenic signalling of insulin glargine and insulin aspart B10 in rats
Improved glycaemic control by switching from insulin NPH to insulin glargine: a retrospective observational study
Investigation of the Physico-Chemical Properties that Enable Co-Formulation of Basal Insulin Degludec with Fast-Acting Insulin Aspart